The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.
Written informed consent.
>=18 years of age.
Moderate-to-severe plaque psoriasis currently treated with a biologic therapy (TNFα antagonist, IL12/23 antagonist, IL17 antagonist).
primary or secondary treatment failure (PASI >= 3 or ΔPASI < 75 and/or DLQI > 5)
Patient appears to be unwilling or unable to comply with the requirements of the study or who, in the opinion of the Investigator, should not participate in the study.
>=3 previous biologic treatments in the last 3 years.
Participation in a clinical trial simultaneous to participation in SW-ATCH.
Any condition preventing prescription of Tildrakizumab according to the SmPC, including but not restricted to any contraindication or history of hypersensitivity or intolerance.